129 related articles for article (PubMed ID: 19597424)
1. CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT.
Ford CD; Asch J; Konopa K; Petersen FB
Bone Marrow Transplant; 2010 Feb; 45(2):403-4. PubMed ID: 19597424
[No Abstract] [Full Text] [Related]
2. Efficacy of lenalidomide in an sAML patient with del 5q relapsing after reduced-intensity allogeneic stem cell transplantation performed in complete remission.
Adès L; Eclache V; Gardin C; Boehrer S; Leroux G; Martiat P; Fenaux P
Bone Marrow Transplant; 2010 Apr; 45(4):791-2. PubMed ID: 19718061
[No Abstract] [Full Text] [Related]
3. Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion.
Peñarrubia MJ; Silvestre LA; Conde J; Cantalapiedra A; Garcia Frade LJ
Leuk Res; 2009 Jun; 33(6):e8-9. PubMed ID: 19168219
[No Abstract] [Full Text] [Related]
4. Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report.
Winkler J; Rech D; Kallert S; Rech J; Meidenbauer N; Roesler W; Mackensen A
Leuk Res; 2010 Oct; 34(10):e270-2. PubMed ID: 20627386
[No Abstract] [Full Text] [Related]
5. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
List A
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide-induced durable hematological and cytogenetic remission in del(5q)-associated de novo acute myeloid leukemia.
Hussein K; Tefferi A
Leuk Res; 2009 Aug; 33(8):e132-3. PubMed ID: 19304324
[No Abstract] [Full Text] [Related]
8. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
9. Life-threatening acute pancreatitis due to thalidomide therapy for chronic graft-versus-host disease.
Chung LW; Yeh SP; Hsieh CY; Liao YM; Huang HH; Lin CY; Chiu CF
Ann Hematol; 2008 May; 87(5):421-3. PubMed ID: 18040684
[No Abstract] [Full Text] [Related]
10. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
[No Abstract] [Full Text] [Related]
11. [Current treatment options for myelodysplastic syndromes].
Nolte F; Hofmann WK
Dtsch Med Wochenschr; 2010 Sep; 135(38):1863-9. PubMed ID: 20842606
[No Abstract] [Full Text] [Related]
12. High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation.
Simpson DR; Nevill TJ; Shepherd JD; Fung HC; Horsman DE; Nantel SH; Vickars LM; Sutherland HJ; Toze CL; Hogge DE; Klingemann HG; Naiman SC; Barnett MJ
Bone Marrow Transplant; 1998 Aug; 22(3):259-64. PubMed ID: 9720739
[TBL] [Abstract][Full Text] [Related]
13. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review.
Oliansky DM; Rizzo JD; Aplan PD; Arceci RJ; Leone L; Ravindranath Y; Sanders JE; Smith FO; Wilmot F; McCarthy PL; Hahn T
Biol Blood Marrow Transplant; 2007 Jan; 13(1):1-25. PubMed ID: 17222748
[TBL] [Abstract][Full Text] [Related]
14. Treatment of adult AML with t(6;11)(q27;q23) by allogeneic hematopoietic SCT in the first CR.
Tamai H; Yamaguchi H; Takahashi S; Tojo A; Hamaguchi H; Kobayashi T; Akiyama H; Sakamaki H; Okumura H; Nakao S; Arai A; Miura O; Tajika K; Inokuchi K; Dan K
Bone Marrow Transplant; 2008 Oct; 42(8):553-4. PubMed ID: 18622415
[No Abstract] [Full Text] [Related]
15. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.
Aversa F; Terenzi A; Tabilio A; Falzetti F; Carotti A; Ballanti S; Felicini R; Falcinelli F; Velardi A; Ruggeri L; Aloisi T; Saab JP; Santucci A; Perruccio K; Martelli MP; Mecucci C; Reisner Y; Martelli MF
J Clin Oncol; 2005 May; 23(15):3447-54. PubMed ID: 15753458
[TBL] [Abstract][Full Text] [Related]
16. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant.
de Lima M; van Besien K; Gajewski J; Khouri I; Andersson B; Korbling M; Champlin R; Giralt S
Bone Marrow Transplant; 2000 Aug; 26(3):333-8. PubMed ID: 10967575
[TBL] [Abstract][Full Text] [Related]
17. Treatment of deletion 5q acute myeloid leukemia with lenalidomide.
Lancet JE; List AF; Moscinski LC
Leukemia; 2007 Mar; 21(3):586-8. PubMed ID: 17230228
[No Abstract] [Full Text] [Related]
18. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
[TBL] [Abstract][Full Text] [Related]
19. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.
Mesa RA; Tefferi A; Li CY; Steensma DP
Leukemia; 2006 Nov; 20(11):2063-4. PubMed ID: 16990762
[No Abstract] [Full Text] [Related]
20. RUNX1 rearrangements in acute myeloblastic leukemia relapsing after hematopoietic stem cell transplantation.
Nadal N; Stephan JL; Cornillon J; Guyotat D; Flandrin P; Campos L
Cancer Genet Cytogenet; 2008 Jan; 180(2):168-9. PubMed ID: 18206548
[No Abstract] [Full Text] [Related]
[Next] [New Search]
